Brachytherapy, alpha-particle radiotherapy
Total Trials
6
As Lead Sponsor
4
As Collaborator
2
Total Enrollment
723
NCT04904120
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 5, 2021
Completion: Sep 20, 2022
NCT05111509
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
Phase: Early Phase 1
Role: Collaborator
Start: Aug 22, 2022
Completion: Jun 30, 2026
NCT05655312
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Phase: Phase 1/2
Start: Jun 1, 2023
Completion: Dec 31, 2029
NCT05636618
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Start: Sep 27, 2023
Completion: Dec 26, 2029
NCT06148636
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Start: Nov 10, 2023
Completion: Nov 20, 2027
NCT06710756
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Start: Apr 28, 2025
Completion: May 28, 2032
Loading map...